On September 26, 2024 ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, reported that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference (Press release, ChromaDex, SEP 26, 2024, View Source [SID1234646874]). Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Company Webcast
The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at View Source or on the Company’s website at chromadex.com. The webcast will also be available for replay following the event.
1×1 Meetings
Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at View Sourceinvreg" target="_blank" title="View Sourceinvreg" rel="nofollow">View Source .
Further information on the conference is available at View Source .
For additional information on ChromaDex, visit www.chromadex.com.